Adipotide

What Is Adipotide?

Adipotide, formally known as FTPP (Fat-Targeted Proapoptotic Peptide), is not a naturally occurring peptide but a lab-engineered construct made of two joined parts. The first part is a short homing sequence that binds specifically to a protein called prohibitin, found on the blood vessels that supply white adipose tissue. The second part is a proapoptotic sequence that, once delivered into those cells, disrupts their mitochondria and triggers cell death.

The concept was developed at the University of Texas Health Science Center at Houston, based on the idea that destroying the blood supply to fat tissue would cause that fat to die off from lack of oxygen and nutrients, rather than working through appetite or metabolism directly. It's worth being direct about where this research stands: after promising results in mice and primates, a Phase 1 human trial began in 2012, but development was discontinued by 2019, and kidney toxicity identified in the primate studies is central to understanding why.

What Adipotide Is Being Researched For

• Fat Tissue Reduction in Animal Models

  The foundational study found that targeting prohibitin with a proapoptotic peptide caused significant fat loss in obese mice by disrupting the blood supply to white adipose tissue.^[1]

• Primate Studies and Metabolic Effects

  A follow-up study in obese rhesus monkeys found that 28 days of treatment produced an average 11% reduction in body weight, along with improvements in insulin resistance, but also identified reversible kidney toxicity as a significant safety finding.^[2]

• Why Human Development Was Discontinued

  The kidney toxicity identified in primate studies is the primary reason cited for discontinuing Adipotide's clinical development. A Phase 1 trial in cancer patients began in 2012, but no broader human efficacy program followed.

How Adipotide Works

• Homing to Fat-Specific Blood Vessels

  Research points to Adipotide's homing sequence binding specifically to prohibitin, a protein found on the endothelial cells that make up the blood vessels supplying white adipose tissue, giving the compound its tissue-specific targeting.^[1]

• Triggering Cell Death in Targeted Vessels

  Research points to the second part of the molecule disrupting mitochondrial membranes once inside the targeted cells, triggering apoptosis, or programmed cell death, in those specific blood vessels rather than in the body generally.^[1]

• Fat Loss Through Vascular Destruction, Not Metabolism

  Research points to the resulting fat loss coming from the fat tissue losing its blood supply and dying off, a fundamentally different mechanism than appetite suppression or metabolic rate changes seen with most other compounds in this space.^[2]

Reconstitution and Handling

Adipotide is typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water before use in a research setting. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

Adipotide represents a genuinely different mechanism than most fat-loss compounds, destroying the blood supply to fat tissue directly rather than working through appetite or metabolism. Its primate data showed real fat loss, but the same studies identified reversible kidney toxicity, which is central to why human development stalled after an initial Phase 1 trial and was ultimately discontinued. Any research interest in this compound should weigh that safety finding as seriously as the fat-loss results.

Frequently Asked Questions

Sources and Research

1. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004;10(6):625-632.
2. Barnhart KF, Christianson DR, Hanley PW, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011;3(108):108ra112.